...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
Reply New Message
Back To Forum List View
Icon president New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
BearDownAZ
Mar 02, 2017 10:51AM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
6
coldnewfie
Mar 02, 2017 06:54PM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
4
SanFrancisco99
Mar 02, 2017 10:43PM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
4
Nextblockbuster
Mar 03, 2017 10:01AM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
SanFrancisco99
Mar 03, 2017 10:14AM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
BearDownAZ
Mar 03, 2017 10:20AM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
2
Nextblockbuster
Mar 03, 2017 11:04AM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
5
BearDownAZ
Mar 03, 2017 01:10PM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
Nextblockbuster
Mar 03, 2017 01:25PM

I guess one could say that. However, the point of the phase I dose escalation trial was by definition to escalate the dose until an unacceptable number adverse events appeared. Now that they've found the maximally tolerated dose in Phase 1, they will soon (hopefully) proceed with Phase 2.

BearDownAZ

3 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply